Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649942 | 1.00 | MAPT (0.33) | MAPTMAPK1NPC1GAARAB9A | |
| SCHEMBL2648257 | 0.86 | SMN1; SMN2 (0.33) | MAPTNPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL2648251 | 0.86 | SMN1; SMN2 (0.33) | MAPTNPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL2648898 | 0.86 | MAPT (0.35) | MAPTMAPK1NPC1GAARAB9A | |
| SCHEMBL2648895 | 0.86 | MAPT (0.35) | MAPTMAPK1NPC1GAARAB9A | |
| SCHEMBL2649907 | 0.85 | SMN1; SMN2 (0.33) | MAPTNPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL2649912 | 0.85 | SMN1; SMN2 (0.33) | MAPTNPC1GAARAB9ASMN1; SMN2 | |
| SCHEMBL2649200 | 0.85 | MAPT (0.34) | MAPTMAPK1NPC1GAARAB9A | |
| SCHEMBL2648938 | 0.85 | S1PR1 (0.35) | MAPTMAPK1NPC1GAARAB9A | |
| SCHEMBL2648944 | 0.85 | S1PR1 (0.35) | MAPTMAPK1NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | MAPT 2197/4885MAPK1 1652/4885NPC1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.